Success Stories: A Researcher IV from Iran in Biomedical Science Gets NIW Approval in Less Than 3 Months with Our Help
Client’s Testimonial:
“Thank you. I was very pleased to work with your law firm.”
On May 9th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher IV in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Researcher IV
Country of Origin: Iran
State of Residence at the Time of Filing: Alabama
Approval Notice Date: May 9th, 2022
Processing Time: 2 months, 17 days
Case Summary:
An expert in the field of biomedical science, our client hailed from Iran and held an M.D. degree. Her proposed endeavor was to continue using various methods informed by biomaterials engineering, animal surgery and imaging, fluorescent imaging, and gene and protein expression analysis in order to advance the development of translational materials and techniques and improve regenerative medicines and cancer treatments. She wanted us to help her file an NIW (National Interest Waiver) petition at USCIS. Given her excellent academic and professional career, our team was quick to recognize that her case had merit.
So we enjoined our team to find out more about her track record and then put these information pieces together for her petition packet. As was expected, they found that her research advancing her proposed endeavor is of great importance because it alleviates quality-of-life issues related to the diagnosis and treatment of some of the world’s deadliest and most widespread diseases. Furthermore, she has contributed substantially to the study of bone and cartilage tissue regeneration, with her efforts yielding progress in the use of grafting to treat conditions such as bone defects, osteoarthritis, and skin wounds. Thus we found that her cutting-edge research is paving the way for the development of effective treatments, therapies, and diagnostic procedures that vastly improve outcomes and quality of life for patients suffering from these health threats.
The process of filing was preceded by finding recommendations from other experts in the field. On our suggestion, she obtained 4 letters of recommendation in all, two coming from each dependent and independent source. Some excerpts from these letters are quoted below:
“[The client] has also provided a deeper understanding of the mechanisms behind the progression of ovarian cancer and its resistance to treatments. As ovarian cancer is the leading cause of gynecological cancer-related deaths, an expanded knowledge of the processes behind ovarian cancer provides researchers with the means to develop new treatments and therapies. Having continually proven herself to be especially proficient at the development of novel techniques to improve the efficacy of widely used and life-saving clinical treatments, there is a sustained and unremitting need for [client’s] continued contributions to biomedical science.”
“[The client] has a uniquely skilled ability to pinpoint and resolve major issues and shortcomings in contemporary medical practice, thereby identifying her as a vital asset to the American research community.”
These statements make clear how important her research is to the world. Her pioneering research into finding novel ways for effectively treating patients suffering from osteoarthritis and related issues is therefore beneficial to U.S. public health. In addition, her investigations into developing optimal therapeutics for use in treating cancer also directly align with U.S. efforts into combating this disease, which alone costs the country over $208 billion each year in medical expenditures. Her work targeting these major health threats has an enormous impact on the quality of life and standard of care for Americans suffering from them.
Parallelly, her research has resulted in 6 peer-reviewed scientific papers (1 of them first-authored). Not only this, but her research has also gone on to influence her peers. That is, these publications have been cited a total of 78 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of biomedical science.
Furthermore, her study has received funding from the NSF and the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases. This funding supports projects with clearly-defined applications and substantial merit that advance healthcare initiatives and outcomes in the United States, with this underscoring the national value of her research.
It was thus no surprise to hear of her case approval. We are delighted to have been a part of this journey of hers.